Rallybio Corporation

Equities

RLYB

US75120L1008

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.85 USD +16.35% Intraday chart for Rallybio Corporation +12.80% -22.59%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
HC Wainwright Cuts Rallybio Price Target to $9 From $12, Maintains Buy Rating MT
Rallybio Corporation Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Rallybio Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : S&P 500 to Open -2- DJ
JMP Securities Adjusts Price Target on Rallybio to $8 From $16, Maintains Market Outperform Rating MT
Wedbush Adjusts Rallybio's Price Target to $13 From $14, Keeps Outperform Rating MT
Jefferies Downgrades Rallybio to Hold From Buy, Adjusts Price Target to $1.50 From $7 MT
Rallybio Corporation Announces the Prioritization of Its Portfolio and a 45% Workforce Reduction to Focus Resources on Its Phase 2-Ready Clinical Stage Programs CI
Transcript : Rallybio Corporation Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 08:15 AM
Evercore ISI Cuts Price Target on Rallybio to $15 From $18, Maintains Outperform Rating MT
Transcript : Rallybio Corporation - Special Call
Rallybio Corporation Announces Preliminary Phase 1 Multiple Ascending Dose Data for RLYB116 CI
Rallybio Says Data From Phase 1 Trial of RLYB212 Support Once-Per-Month Dosing Regimen in Planned Phase 2 Study MT
Rallybio Corporation Announces Preliminary Multiple Dose Data from the Completed Phase 1 Safety and Pharmacokinetics Study for RLYB212 CI
HC Wainwright Trims Rallybio Price Target to $17 From $18, Maintains Buy Rating MT
Wedbush Lowers Rallybio's PT to $14 From $16, Retains Cash Runway Guidance But Increases Discount Rate; Maintains Outperform Rating MT
Rallybio Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
North American Morning Briefing : Stocks Look to -2- DJ
Rallybio Corporation Announces Acceptance of FNAIT Natural History Study Abstract for Presentation at the 65th American Society of Hematology Annual Meeting CI
Rallybio Corporation Presents Phase 1 Single Ascending Dose Data for RLYB116, Innovative Subcutaneously Injected Inhibitor of Complement Component 5 CI
Rallybio Corporation Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
North American Morning Briefing : Investors Await -2- DJ
Rallybio Promotes Stephen Uden to CEO; Martin Mackay Named Executive Chairman MT
Rallybio Corporation Announces Chief Executive Officer Changes CI
Chart Rallybio Corporation
More charts
Rallybio Corporation is a clinical-stage biotechnology company engaged in developing and commercializing life-transforming therapies for patients with severe and rare diseases. It has a pipeline of product candidates aimed at addressing diseases with unmet medical needs in the areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. It has two clinical-stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Its other product candidates include RLYB114, RLYB331 and ENPP1 Program. Its second C5 inhibitor, RLYB114, is a pegylated C5-targeted Affibody molecule with PK properties designed for the treatment of complement-mediated ophthalmic diseases. RLYB331 is for the treatment of severe anemia.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
1.85 USD
Average target price
11.25 USD
Spread / Average Target
+508.11%
Consensus
  1. Stock
  2. Equities
  3. Stock Rallybio Corporation - Nasdaq
  4. News Rallybio Corporation
  5. Rallybio Secures Global Rights to Sanofi's Antibody Candidate to Treat Anemia